Efficacy and safety of BIA 9-1067 in idiopathic Parkinson�s disease patients with �wearing-off� phenomenon treated with levodopa plus a dopa decarboxylase inhibitor (DDCI): a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinic

To investigate the efficacy of 2 different doses of BIA 9-1067 (25 mg and 50 mg), administered once a day, compared with placebo when administered with the existing treatment of L-DOPA plus a DDCI, in patients with PD and end-of-dose motor fluctuations.